公开(公告)号：CA2947512A1

公开(公告)日：2015-11-05

申请号：CA2947512

申请日：2015-04-21

Applicant: STICHTING VUMC ,  UNIV GRANADA

Inventor： PEGTEL DIRK MICHIEL ,  KOPPERS-LALIC DANIJELA ,  WURDINGER TOM ,  BIJNSDORP IRENE ,  HACKENBERG MICHAEL

IPC: C12Q1/68 ,  C12N15/11 ,  C12N15/113

Abstract: The present disclosure provides small ncRNAs as biomarkers for classifying the health status of an individual. The disclosure also provides screening methods for identifying ncRNA biomarkers.

公开(公告)号：EP4314079A1

公开(公告)日：2024-02-07

申请号：EP22776458.6

申请日：2022-03-22

Applicant: Memorial Sloan-Kettering Cancer Center ,  Sloan-Kettering Institute for Cancer Research ,  Memorial Hospital for Cancer and Allied Diseases ,  Stichting VUmc

Inventor： SADELAIN, Michel ,  THEMELI, Maria ,  SJÖSTRAND, Maria ,  KATSAROU, Afroditi

IPC: C07K16/30 ,  C07K16/40 ,  A61P35/00 ,  A61P35/02 ,  A61K35/17 ,  A61P37/02

公开(公告)号：EP4046639A1

公开(公告)日：2022-08-24

申请号：EP21158504.7

申请日：2021-02-22

Applicant: Stichting VUmc

Inventor： AMAN, Jannes ,  BOGAARD, Herman Jan ,  DE MAN E/V HANDOKO, Frances Sarah ,  DUIJVELAAR, Erik ,  VONK NOORDEGRAAF, Antonie

IPC: A61K31/506 ,  A61K31/573 ,  A61K45/06 ,  A61P11/00 ,  A61P31/14

Abstract: The invention relates to an inhibitor of Abelson Tyrosine-Protein Kinase 2 ( Abl2 ), for use in a method of treating an individual suffering from, or at risk of suffering from, virally induced pneumonitis.

公开(公告)号：EP3793599A1

公开(公告)日：2021-03-24

申请号：EP19739378.8

申请日：2019-05-15

Applicant: Janssen Biotech, Inc. ,  Stichting VUmc

Inventor： ADAMS, Homer ,  GAUDET, Francois ,  FRERICHS, Kris ,  VAN DE DONK, Niels ,  VERKLEIJ, Christie

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

公开(公告)号：EP2686677B1

公开(公告)日：2018-10-03

申请号：EP12702324.0

申请日：2012-01-16

Applicant: Stichting VUmc

Inventor： WÜRDINGER, Thomas ,  NILSSON, Rolf Jonas

IPC: C12Q1/6886

CPC classification number: C12Q1/6834 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The present invention relates to a method of analysing a blood sample of a subject for the presence of a disease marker, said method comprising the steps of a) extracting nucleic acid from anucleated blood cells in said blood sample to provide an anucleated blood cells-extracted nucleic acid fraction, and b) analysing said anucleated blood cells-extracted nucleic acid fraction for the presence of a disease marker, wherein said disease marker is a disease-specific mutation in a gene of a cell of said subject, or wherein said disease marker is a disease-specific expression profile of genes of a cell of said subject.

公开(公告)号：EP3137626B1

公开(公告)日：2020-12-02

申请号：EP15717179.4

申请日：2015-04-21

Applicant: Stichting VUmc ,  Universidad de Granada

Inventor： PEGTEL, Dirk Michiel ,  KOPPERS-LALIC, Danijela ,  WURDINGER, Tom ,  BIJNSDORP, Irene ,  HACKENBERG, Michael

IPC: C12Q1/6809 ,  C12Q1/6886

公开(公告)号：EP3671215A1

公开(公告)日：2020-06-24

申请号：EP19201973.5

申请日：2013-04-26

Applicant: Stichting VUmc

Inventor： Bosch, Linda Janna Willemien ,  De Wit, Meike ,  Pinto Morais De Carvalho, Beatriz ,  Fijneman, Remondus Johannes Adriaan ,  Meijer, Gerrit Albert ,  Jimenez, Cornelia Ramona ,  Piersma, Sander Rogier ,  Pham, Viet Thang ,  Oudgenoeg, Gideon

IPC: G01N33/574

Abstract: The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in Table 1 and/or Table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer.

公开(公告)号：EP3494235A1

公开(公告)日：2019-06-12

申请号：EP18710554.9

申请日：2018-02-19

Applicant: Stichting VUmc

Inventor： WURDINGER, Thomas ,  BEST, Myron Ghislain

IPC: C12Q1/68 ,  C12Q1/6886

公开(公告)号：EP3253393A1

公开(公告)日：2017-12-13

申请号：EP15841108.2

申请日：2015-12-22

Applicant: Stichting VUmc ,  A-skin Holding B.V.

Inventor： GIBBS, Susan ,  SCHEPER, Riekeld Johannes

IPC: A61K35/33 ,  A61K35/36 ,  C12N5/071 ,  C12N5/077 ,  A61P17/02

CPC classification number: A61K35/36 ,  A61K35/33 ,  C12N5/0629 ,  C12N5/0656 ,  C12N2502/094 ,  C12N2502/1323

Abstract: The present disclosure relates to a method for producing a composition, wherein the method comprises the steps of co-culturing immortalized fibroblasts and immortalized keratinocytes, thereby producing secretion; separating the secretion from the fibroblasts and keratinocytes; and providing a pharmaceutically acceptable composition comprising the secretion. The present disclosure also relates to the composition obtainable by the method, wherein the composition preferably is a pharmaceutical composition for medical use, preferably for use in the treatment of a wound, preferably a chronic or acute wound.

公开(公告)号：CL2021002267A1

公开(公告)日：2022-04-01

申请号：CL2021002267

申请日：2021-08-27

Applicant: JANSSEN BIOTECH INC ,  STICHTING VUMC

Inventor： GAUDET FRANCOIS ,  ADAMS HOMER ,  VAN DE DONK NIELS ,  VERLEIJ CHRISTIE C P M ,  FRERICHS KRIS

IPC: C07K16/28

Abstract: La descripción proporciona métodos para tratar un cáncer y/o destruir células tumorales en un sujeto, que comprende administrar una cantidad terapéuticamente eficaz de un anticuerpo anti-CD38 y un agente terapéutico para el redireccionamiento de células T al sujeto para tratar el cáncer. La presente descripción proporciona un método para potenciar la eficacia de un agente terapéutico para el redireccionamiento de células T en un sujeto que tiene un cáncer, que comprende administrar al sujeto un anticuerpo anti-CD38. La descripción también proporciona un método para tratar un mieloma múltiple en un sujeto, que comprende administrar una cantidad terapéuticamente eficaz de un anticuerpo biespecífico BCMAxCDS y un anticuerpo anti-CD38 al sujeto para tratar el mieloma múltiple. La descripción también proporciona una combinación farmacéutica que comprende un anticuerpo biespecífico GPRC5DxCD3. La descripción también proporciona un kit que comprende una composición farmacéutica que comprende un anticuerpo biespecífico BCMAxCD3 y un anticuerpo anti-CD38.